The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a huge mover today! About 657,817 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 47.29% since April 18, 2016 and is uptrending. It has outperformed by 42.86% the S&P500.
The move comes after 8 months negative chart setup for the $1.16B company. It was reported on Nov, 18 by Barchart.com. We have $20.35 PT which if reached, will make NASDAQ:SUPN worth $104.40 million less.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) earned “Buy” rating by Jefferies on Thursday, August 4. The firm earned “Outperform” rating on Thursday, November 5 by Northland Capital. The stock has “Hold” rating given by Zacks on Wednesday, August 26. The firm earned “Market Perform” rating on Monday, July 18 by Northland Capital. Northland Capital initiated Supernus Pharmaceuticals Inc (NASDAQ:SUPN) on Wednesday, October 28 with “Outperform” rating. The stock has “Neutral” rating given by Piper Jaffray on Monday, July 18.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.22, from 1.26 in 2016Q1. The ratio worsened, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Dupont Management has 81,701 shares for 0.04% of their US portfolio. Envestnet Asset Mgmt Incorporated accumulated 37,681 shares or 0% of the stock. Teachers accumulated 0.02% or 604,277 shares. Oxford Asset Mngmt, a United Kingdom-based fund reported 278,668 shares. Arizona State Retirement Sys accumulated 0.01% or 18,001 shares. White Pine Limited Liability Company accumulated 0.37% or 43,100 shares. Ubs Asset Mgmt Americas Inc accumulated 0% or 17,500 shares. Aqr Cap Mgmt Lc holds 0.01% or 149,156 shares in its portfolio. Cam Gp Hldgs A S last reported 0.05% of its portfolio in the stock. Raymond James Assocs has 21,024 shares for 0% of their US portfolio. Nicholas Lp holds 0.19% or 136,776 shares in its portfolio. Lazard Asset Ltd Co accumulated 0.01% or 143,300 shares. Granahan Inv Ma, a Massachusetts-based fund reported 860,969 shares. Ls Advsr Limited Co holds 0% or 1,434 shares in its portfolio. Thomson Horstmann Bryant Inc has 0.09% invested in the company for 34,188 shares.
Insider Transactions: Since September 16, 2016, the stock had 0 insider purchases, and 1 sale for $50,000 net activity. $50,000 worth of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) was sold by PATRICK GREGORY S on Friday, September 16.
Another recent and important Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news was published by Investorplace.com which published an article titled: “Supernus Pharmaceuticals Inc (SUPN) Stock Dips Despite Positive ADHD Data” on October 11, 2016.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.